VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2018 | Benefits of MRD use in ALL

In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, comments on the benefits of the use of measurable residual disease (MRD) to inform treatment decisions rather than having to rely on morphology assessments. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter